STATE OF THE ART PAPER
Molecular mechanisms of statin intolerance
 
More details
Hide details
Submission date: 2016-03-21
Acceptance date: 2016-03-21
Online publication date: 2016-05-18
Publication date: 2016-05-16
 
Arch Med Sci 2016;12(3):645–658
 
KEYWORDS
TOPICS
ABSTRACT
Statins reduce cardiovascular morbidity and mortality in primary and secondary prevention. Despite their efficacy, many persons are unable to tolerate statins due to adverse events such as hepatotoxicity and myalgia/myopathy. In the case of most patients, it seems that mild-to-moderate abnormalities in liver and muscle enzymes are not serious adverse effects and do not outweigh the benefits of coronary heart disease risk reduction. The risk for mortality or permanent organ damage ascribed to statin use is very small and limited to cases of myopathy and rhabdomyolysis. Statin-induced muscle-related adverse events comprise a highly heterogeneous clinical disorder with numerous, complex etiologies and a variety of genetic backgrounds. Every patient who presents with statin-related side effects cannot undergo the type of exhaustive molecular characterization that would include all of these mechanisms. Frequently the only solution is to either discontinue statin therapy/reduce the dose or attempt intermittent dosing strategies at a low dose.
eISSN:1896-9151
ISSN:1734-1922